FDA-approved GLP-1 receptor agonists include semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon)
Safety monitoring requirements Monitoring your health while on these medications is super important
Board Certified Nurse Practitioner APRN NPI: 1467595330 Board Certified Physician MD NPI: 1780944918 Prescription products require an online consultation with a physician
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms
This stabilization period allows the body to reach its new baseline and ensures surgical results will be long-lasting
days 1 to 30): 1.5 mg orally once a day Dose escalation (days 31 to 60): 4 mg orally once a day Maintenance dose (day 61 and onward): If no additional glycemic control is needed: Maintain at 4 mg orally once a day
